MirimGENE has been selected as an official nominee in the Best Startup category at Prix Galien USA 2026.
The Prix Galien USA celebrates scientific innovation in medicines, medical technologies, and healthcare solutions that contribute to human health. Organized by The Galien Foundation, the awards bring together pioneering companies advancing the next generation of treatments and technologies.
MirimGENE is developing WITheranostics™, a platform that connects diagnosis and treatment for intractable inflammatory and immune-mediated diseases by targeting WARS1, a key mediator of inflammatory responses. Through this approach, the company is exploring new therapeutic strategies to address the limitations of existing treatments.
Building on this nomination, MirimGENE remains committed to advancing its research and development to bring new treatment possibilities to patients with intractable inflammatory and immune-mediated diseases.